2020
DOI: 10.2217/fon-2020-0784
|View full text |Cite
|
Sign up to set email alerts
|

Plain Language Summary of Publication articles: helping disseminate published scientific articles to patients

Abstract: Future Science Group (FSG) is keen to recognize and promote the vital role of patients in medical and scientific research, and as such, has introduced a new article type to its collection -the Plain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 13 publications
(11 citation statements)
references
References 4 publications
0
11
0
Order By: Relevance
“…Lastly, we found criteria that referred to the characteristics of the Contextual Information category [ 8 , 9 , 15 , 18 , 20 , 22 – 24 , 27 , 38 , 42 , 50 , 52 , 55 , 57 , 59 , 63 , 64 , 67 , 72 , 73 , 75 , 78 , 80 , 84 , 86 91 ]: For example, publications included specifications regarding PLS authorship [ 8 , 9 , 38 , 64 , 80 , 87 ], and whether the submission of a PLS is or should be mandatory [ 18 , 75 , 89 ]. Another main contextual subject focused on the writing and publication process: There were specifications of where or how the PLS is or should be published (e.g., open access publishing [see 9 , 80 ]) and some articles included detailed descriptions outlining the writing and publishing process of the PLS [ 52 , 73 , 78 , 84 , 90 ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Lastly, we found criteria that referred to the characteristics of the Contextual Information category [ 8 , 9 , 15 , 18 , 20 , 22 – 24 , 27 , 38 , 42 , 50 , 52 , 55 , 57 , 59 , 63 , 64 , 67 , 72 , 73 , 75 , 78 , 80 , 84 , 86 91 ]: For example, publications included specifications regarding PLS authorship [ 8 , 9 , 38 , 64 , 80 , 87 ], and whether the submission of a PLS is or should be mandatory [ 18 , 75 , 89 ]. Another main contextual subject focused on the writing and publication process: There were specifications of where or how the PLS is or should be published (e.g., open access publishing [see 9 , 80 ]) and some articles included detailed descriptions outlining the writing and publishing process of the PLS [ 52 , 73 , 78 , 84 , 90 ].…”
Section: Resultsmentioning
confidence: 99%
“…Another main contextual subject focused on the writing and publication process: There were specifications of where or how the PLS is or should be published (e.g., open access publishing [see 9 , 80 ]) and some articles included detailed descriptions outlining the writing and publishing process of the PLS [ 52 , 73 , 78 , 84 , 90 ]. Occasionally, recommendations were made to engage patients or members of the public in the PLS creation process [ 73 , 84 , 90 , 91 ].…”
Section: Resultsmentioning
confidence: 99%
“…Clarification of document distinctions is provided in Table 1. [2][3][4]12,13,[24][25][26][27] As an example of the differences in readability and target reading ages between lay summaries and PLS, selected excerpts 28,29 showed the readability consensus was 12-14 years old for the lay summaries and 18-19 years old for the PLS (Figure 1, 28 Figure 2 29 ).…”
Section: Document Distinctions and Example Readability Comparisonsmentioning
confidence: 99%
“…These are: l Regulatory lay summaries 2 l Publication-associated plain language summaries (PLS) 3 l Standalone plain language summaries of publications (PLSPs). 4 These three different document types each have their own distinct purpose, scope, and audience; however, there is limited clarity regarding the terminology used when referring to these documents.…”
Section: Introductionmentioning
confidence: 99%
“…An important part of this is ensuring that the output from medical research is available in a format accessible to all. Future Science Group is keen to recognize and support patients, both as contributors and readers [1]. To this end, Future Oncology recently published our first Plain Language Summary of Publication [2], which provides a visually enriched summary of the recently published ENLIVEN study, investigating pexidartinib for tenosynovial giant cell tumor [3].…”
Section: Content Highlights From 2020mentioning
confidence: 99%